Shared on08 Aug 25Fair value Decreased 5.31%
Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.51%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 37.2x to 41.2x.
Shared on09 Apr 25Fair value Increased 93%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.